Bormioli Pharma has unveiled its highly anticipated third edition of the Sustainability Report. 

This comprehensive document showcases the significant progress made by Bormioli Pharma in driving sustainable growth within the communities it serves, while also reaffirming its steadfast support for the pharmaceutical industry's transition toward environmentally friendly solutions.

The report highlights several key initiatives undertaken by Bormioli Pharma throughout the year, demonstrating its proactive approach to sustainability. The reinforcement of the ESG team and governance structure has led to the establishment of strong processes outlined in its ESG Policy.

In alignment with its sustainability targets, Bormioli Pharma remains dedicated to achieving a 30 percent reduction in carbon intensity and a 41 percent reduction in Water Withdrawal Intensity by 2030, compared to a 2021 baseline. The company has also made significant strides in increasing the share of sustainable materials in its products, nearing its 50 percent target by 2025 with 45 percent achieved in 2023.

Andrea Lodetti, CEO of Bormioli Pharma, emphasized the company's role as a catalyst for responsible growth within the pharmaceutical sector. He remarked, "In 2023, we have worked energetically to be an important driver of responsible growth, remarking our role as a partner of the pharmaceutical industry in developing increasingly widespread, effective, and sustainable medical practices." Lodetti highlighted the expansion of the EcoPositive sustainable packaging offering as a tangible demonstration of Bormioli Pharma's commitment to supporting the EU's goals for sustainable packaging.

Furthermore, Bormioli Pharma is actively promoting a culture of Diversity & Inclusion across its organization, aiming to train 95 percent of employees on these topics by 2025. The company also seeks to assess 90 percent of its suppliers on the international EcoVadis platform by 2026, ensuring a supply chain that aligns with its high standards for ESG performance.

The economic results for 2023 reflect Bormioli Pharma's success, with an impressive 18 percent increase in revenues compared to the previous year. This growth reaffirms the effectiveness of the company's strategic decisions and its ability to generate long-term value for stakeholders while upholding its commitment to people, the environment, and society.

Bormioli Pharma, with its portfolio of packaging solutions and a workforce of over 1,400 employees across Europe, continues to be a driving force in the pharmaceutical industry, reporting annual sales of approximately EUR 370 million.